Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer

Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle

(2017) Lorenzo Gerratana et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs

(2017) Giorgio Mustacchi et al.   JOURNAL OF MEDICAL ECONOMICS

Induction chemotherapy followed by chemoradiotherapy and TME for high-risk locally advanced rectal cancer with and without synchronous resectable metastases.

(2017) Carla Hajj et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States

(2016) Vakaramoko Diaby et al.   BREAST CANCER RESEARCH AND TREATMENT

Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer

(2016) Henry W.C. Leung et al.   CLINICAL THERAPEUTICS

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2016) Ben Y. Durkee et al.   JOURNAL OF CLINICAL ONCOLOGY

The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan

(2016) Hui-Chu Lang et al.   JOURNAL OF MEDICAL ECONOMICS

HER2-positive metastatic breast cancer: A changing scenario

(2015) G. Mustacchi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost–effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus

(2014) Panagiotis Petrou et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada

(2014) C. L. Attard et al.   JOURNAL OF MEDICAL ECONOMICS

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

(2013) A. Schneeweiss et al.   ANNALS OF ONCOLOGY

Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2-positivo en Colombia

(2013) Jefferson Antonio Buendía et al.   Biomedica

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

(2013) Nadia Harbeck et al.   Breast Care

A systematic review of dual targeting in HER2-positive breast cancer

(2013) Iben Kümler et al.   CANCER TREATMENT REVIEWS

Breast cancer research in Asia: Adopt or adapt Western knowledge?

(2012) Nirmala Bhoo-Pathy et al.   EUROPEAN JOURNAL OF CANCER

Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer

(2012) L. Hedden et al.   ONCOLOGIST

Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome

(2011) Jonathan Krell et al.   Clinical Breast Cancer

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

(2009) Wen Chen et al.   VALUE IN HEALTH

Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland

(2008) Timo Purmonen et al.   CLINICAL THERAPEUTICS